Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment

被引：0
|
作者：
Sands, Bruce E. [1 ]
Kobayashi, Taku [2 ]
Wu, Jianmin [3 ]
Wang, Isabella Yali [3 ]
Zhu, Baojin [3 ]
Redondo, Isabel [4 ]
Peyrin-Biroulet, Laurent [5 ,6 ]
Walsh, Alissa [7 ]
Magro, Fernando [8 ,9 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Kitasato Univ, Kitasato Inst Hosp, Minato City, Tokyo, Japan
[3] Eli Lilly & Co, Indianapolis, IN USA
[4] Eli Lilly & Co, Lisbon, Portugal
[5] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM,NGERE, Vandoeuvre Les Nancy, France
[6] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[7] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[8] Univ Porto, Porto, Portugal
[9] Ctr Hosp, Porto, Portugal
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001035164.22459.94
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1449
引用
收藏
页码：S1042 / S1043
页数：2
相关论文
共 50 条
  • [31] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
    J. Ignacio Fernández-Blanco
    Guillermo Fernández-Díaz
    Carlos Cara
    María I. Vera
    David Olivares
    Carlos Taxonera
    Digestive Diseases and Sciences, 2018, 63 : 731 - 737
  • [32] CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
    Laharie, D.
    Siegel, C. A.
    Samaan, K.
    Fisher, D. A.
    Morris, N.
    Redondo, I.
    Dulai, P. S.
    Jairath, V.
    Gisbert, J. P.
    Matsuoka, K.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S163 - S164
  • [33] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023, : 1479 - 1491
  • [34] BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
    Stargardter, Matthew
    Upadhyay, Navneet
    Raj, Sayooj
    Fisher, Deborah
    Creveling, Thomas
    Bires, Nicholas
    Johnson, Nate
    Milev, Sandra
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S43 - S44
  • [35] Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy
    Laharie, David
    Siegel, Corey A.
    Samaan, Karen
    Fischer, Deborah
    Morris, Nathan
    Redondo, Isabel
    Dulai, Parambir S.
    Jairath, Vipul
    Gisbert, Javier P.
    Matsuoka, Katsuyoshi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S635 - S635
  • [36] The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab
    Panaccione, R.
    Sapin, C.
    Chan-Diehl, F. W.
    Moses, R. E.
    Siegmund, B.
    Walsh, A.
    Kobayashi, T.
    Parambir, D. S.
    Travis, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I167 - I168
  • [37] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023,
  • [38] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Pai, Rish
    Canavan, James
    Tuttle, Jay
    Durante, Michael
    Arora, Vipin
    Milch, Catherine
    Harpaz, Noam
    D'Haens, Geert R.
    Sands, Bruce E.
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1187 - S1187
  • [39] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Laiyi Chua
    Stuart Friedrich
    Xin Cindy Zhang
    Clinical Pharmacokinetics, 2023, 62 (10) : 1479 - 1491
  • [40] SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Siegel, Corey A.
    Rubin, David T.
    Long, Millie D.
    Danese, Silvio
    Cross, Raymond K.
    Armuzzi, Alessandro
    Dignass, Axel
    Kobayashi, Taku
    Faye, Adam S.
    Lama, Sonie
    Charles, Lorna
    Cetin, Volkan
    Petersen, AnnKatrin
    Wu, Hsiuanlin
    Wang, Dong
    Jain, Anjali
    Sabino, Joao
    GASTROENTEROLOGY, 2024, 166 (05) : S805 - S806
12345